China Universal Asset Management Co. Ltd. Increases Holdings in Gilead Sciences, Inc. $GILD

China Universal Asset Management Co. Ltd. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 161,155 shares of the biopharmaceutical company’s stock after buying an additional 6,680 shares during the quarter. Gilead Sciences makes up approximately 1.5% of China Universal Asset Management Co. Ltd.’s portfolio, making the stock its 11th biggest position. China Universal Asset Management Co. Ltd.’s holdings in Gilead Sciences were worth $17,888,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of GILD. Berkeley Capital Partners LLC boosted its stake in shares of Gilead Sciences by 7.4% in the 3rd quarter. Berkeley Capital Partners LLC now owns 2,023 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 139 shares in the last quarter. Jupiter Asset Management Ltd. bought a new stake in Gilead Sciences in the third quarter worth $1,012,000. Y.D. More Investments Ltd purchased a new stake in Gilead Sciences during the third quarter valued at about $37,000. D Orazio & Associates Inc. grew its stake in shares of Gilead Sciences by 19.5% during the third quarter. D Orazio & Associates Inc. now owns 6,376 shares of the biopharmaceutical company’s stock valued at $708,000 after buying an additional 1,042 shares during the last quarter. Finally, ICICI Prudential Asset Management Co Ltd increased its holdings in shares of Gilead Sciences by 22.2% in the third quarter. ICICI Prudential Asset Management Co Ltd now owns 19,055 shares of the biopharmaceutical company’s stock worth $2,115,000 after buying an additional 3,466 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director directly owned 8,920 shares of the company’s stock, valued at $1,101,620. The trade was a 35.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total value of $463,290.00. Following the transaction, the chief financial officer directly owned 167,779 shares of the company’s stock, valued at approximately $25,910,110.97. This trade represents a 1.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 319,891 shares of company stock worth $45,091,556 in the last ninety days. 0.27% of the stock is owned by company insiders.

Gilead Sciences Stock Down 1.1%

Shares of NASDAQ:GILD opened at $151.12 on Friday. The firm has a market capitalization of $187.49 billion, a P/E ratio of 22.32, a P/E/G ratio of 2.03 and a beta of 0.36. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.68. The stock has a 50 day moving average price of $132.85 and a 200-day moving average price of $123.38. Gilead Sciences, Inc. has a 52-week low of $93.37 and a 52-week high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The company had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. During the same period in the prior year, the firm earned $1.90 earnings per share. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be paid a dividend of $0.82 per share. The ex-dividend date of this dividend is Friday, March 13th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s payout ratio is presently 46.68%.

Gilead Sciences News Roundup

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Rothschild & Co Redburn raised its price target to $170 and kept a Buy rating, reinforcing upside expectations tied to Gilead’s core franchises and supporting potential inflows. Rothschild PT Raise
• Positive Sentiment: Mizuho also lifted its target to $170 and maintained an Outperform rating — another analyst upgrade adding to buy-side momentum. Mizuho PT Raise
• Positive Sentiment: Q4 results showed an EPS beat and revenue beat, and management set FY‑2026 guidance at $8.45–$8.85 — this reinforces the earnings narrative (HIV franchise strength and durable cash flow) that underpins analyst optimism. Post-earnings Analyst Coverage
• Neutral Sentiment: Maxim Group reiterated a Hold rating, noting much of the HIV growth may be priced in and diversification remains limited — a cautious view that tempers aggressive upside. Maxim / Hold
• Neutral Sentiment: Analyst Q&A and feature pieces (including performance retrospectives) are providing context for investors but are mixed in directional impact — useful for positioning but unlikely to move price materially alone. Analyst Q&A
• Negative Sentiment: Insider selling: CFO Andrew Dickinson sold 3,000 shares at ~ $154.43 (Form 4 filing). Leadership sales often add near‑term selling pressure or raise governance questions for some investors. CFO Form 4
• Negative Sentiment: Significant insider sale: Johanna Mercier sold 28,000 shares at ~ $154.44 (an ~18.9% reduction in her holding), a larger single insider transaction that can weigh on investor confidence. Mercier Form 4

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on GILD shares. Scotiabank raised their price target on Gilead Sciences from $140.00 to $177.00 and gave the stock a “sector outperform” rating in a research report on Wednesday, February 11th. Truist Financial increased their price objective on Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a research note on Wednesday, February 11th. Mizuho raised their target price on shares of Gilead Sciences from $140.00 to $170.00 and gave the stock an “outperform” rating in a report on Wednesday. Daiwa Securities Group upped their price target on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a report on Thursday, November 13th. Finally, Rothschild & Co Redburn raised their price target on shares of Gilead Sciences from $159.00 to $170.00 and gave the stock a “buy” rating in a report on Tuesday. Twenty-three research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average price target of $154.21.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.